Sandoz Q3 2024 Sales Boosted by Biosimilars and Generics, Up 12% YOY
Switzerland-based Sandoz (SWX: SDZ) has published its financial statements for the third quarter of 2024,...
Finanical Reports
Junshi Biosciences Reports Q3 2024 Financials with Revenue Growth and Narrowed Losses
Junshi Biosciences (HKG: 1877; SHA: 688180) has released its financial results for the third quarter...
Eli Lilly Reports 20% YOY Revenue Growth in Q3 2024 Driven by Mounjaro and Zepbound
US pharmaceutical giant Eli Lilly and Company (NYSE: LLY) has reported its financial results for...
GSK Reports Mixed Q3 2024 Results with 2% YOY Revenue Growth
UK pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK) has released its financial report for the third...
AbbVie Reports Q3 2024 Revenue Growth, Strength in Immunology and Neuroscience
US pharmaceutical company AbbVie (NYSE: ABBV) has announced its financial results for the third quarter...
Pfizer Reports Strong Q3 Results, Boosts 2024 Guidance to $61-$64 Billion
Pfizer Inc. (NYSE: PFE) released its Q3 2024 financial results, reporting revenues of $17.702 billion...
Mindray Reports Q3 2024 Financials: International Revenues Surge Over 18% Amid Domestic Challenges
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (SHE: 300760) reported its Q3 2024 financial results, revealing...
Fosun Pharmaceutical Reports Q3 2024 Revenue Growth and R&D Progress
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has released its financial report...
Shanghai Pharmaceuticals Reports Q3 2024 Revenue Growth, Strengthens Drug Pipeline
China’s Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607) has announced its financial results for the...
WuXi AppTec Reports Q3 2024 Revenues of RMB 10.46 Billion Amid Biosecure Act Challenges
WuXi AppTec Co., Ltd (SHA: 603259), the China-based Contract Development and Manufacturing Organization (CDMO) facing...
Boston Scientific Reports 19.5% YOY Increase in Q3 Net Sales, Driven by New Product Launches and Market Expansion
Boston Scientific Corporation (NYSE: BSX), a leading medical device manufacturer in the U.S., has announced...
Sunshine Guojian Pharma Reports Q3 Revenue Growth and Advances in Clinical Trials
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA: 688336), a subsidiary of 3SBio Inc. (HKG: 1530),...
Abbott Laboratories Posts 9.4% Q3 Sales Growth, Driven by Medical Devices and Pharmaceuticals
Abbott Laboratories (NYSE: ABT), a U.S.-based healthcare giant, has reported its financial results for the...
J&J Reports Q3 2024 Revenue Growth, Raises Full-Year Guidance on Strong Pipeline Progress
Johnson & Johnson (J&J, NYSE: JNJ) has released its financial report for the third quarter...
3D Medicines’ H1’24 Financials Reflect Increased Comprehensive Loss Amid Revenue Decline
3D Medicines (HKG: 1244), a China-based oncology specialist, has released its financial report for the...
InnoCare Pharma’s H1 2024 Revenue Boosted by Orelabrutinib, Anticipates Minjuvi Approval in 2025
InnoCare Pharma (HKG: 9969; SHA: 688428), a biopharmaceutical company based in China, has released its...
Sihuan Pharmaceutical Sees Aesthetics and Biopharma Growth Amid Overall Revenue Dip
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), a leading pharmaceutical company in China, has released...
Sichuan Kelun-Biotech Reports 32.2% Revenue Growth in 2024 H1, Driven by MSD Partnership
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced its financial results for the first...
Harbour BioMed’s 2024 H1 Revenues Decline Amid R&D Optimization and Pipeline Advancements
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands,...
MicuRx Pharmaceuticals Reports 44% Revenue Growth and Increased R&D Spending in 2024 H1
SHANGHAI—MicuRx Pharmaceuticals (SHA: 688373), a Shanghai-based developer of antibacterial drugs, has released its financial report...